By Jessica Sier 
 

Roche Holding AG said Tuesday that it will invest and codevelop a lung-cancer drug with U.S. company Blueprint Medicines Corp.

The two companies will develop pralsetinib, a therapy for people with RET-altered nonsmall cell lung cancer, various types of thyroid cancer and other solid tumours.

The Swiss drug company said it will pay $675 million in cash upfront, as well as a $100 million equity investment in Blueprint Medicines.

The U.S.-based drug company is eligible to receive up to $927 million in potential milestones, plus royalties on net product sales outside the U.S.

Roche said the agreement gives it exclusive rights for global co-development and commercialization outside the U.S. and excluding Greater China.

 

Write to Jessica Sier at jessica.sier@wsj.com

 

(END) Dow Jones Newswires

July 14, 2020 01:53 ET (05:53 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Roche (QX) Charts.